MCID: TRC022
MIFTS: 45

Tricuspid Valve Insufficiency

Categories: Cardiovascular diseases

Aliases & Classifications for Tricuspid Valve Insufficiency

MalaCards integrated aliases for Tricuspid Valve Insufficiency:

Name: Tricuspid Valve Insufficiency 12 43 15 71
Tricuspid Regurgitation 12 29 54 6 15
Tricuspid Valve Regurgitation 12
Tricuspid Incompetence 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4080
MeSH 43 D014262
UMLS 71 C0040961

Summaries for Tricuspid Valve Insufficiency

Disease Ontology : 12 A tricuspid valve disease that is characterized by failure of the heart's tricuspid valve to close properly during systole. As a result, with each heart beat, blood is pumped out from the right side of the heart in the opposite direction to normal.

MalaCards based summary : Tricuspid Valve Insufficiency, also known as tricuspid regurgitation, is related to heart septal defect and cardiogenic shock. An important gene associated with Tricuspid Valve Insufficiency is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), and among its related pathways/superpathways is Development_Leptin signaling via JAK/STAT and MAPK cascades. The drugs Tolvaptan and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and lung, and related phenotypes are cardiovascular system and normal

Related Diseases for Tricuspid Valve Insufficiency

Diseases in the Tricuspid Valve Disease family:

Tricuspid Valve Insufficiency

Diseases related to Tricuspid Valve Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 418)
# Related Disease Score Top Affiliating Genes
1 heart septal defect 31.2 ZIC3 PTPN11 F2
2 cardiogenic shock 31.2 NPPB CRP
3 pulmonary hypertension, primary, 1 31.0 NPPB EDN1 BMPR2
4 right bundle branch block 30.9 NPPB BMPR2 ACE
5 hypoplastic left heart syndrome 30.8 ZIC3 NPPB ACE
6 left bundle branch hemiblock 30.7 NPPB CRP ACE
7 endocarditis 30.7 F2 CRP ALB
8 sickle cell anemia 30.7 F2 EDN1 ALB
9 aortic valve disease 2 30.6 NPPB CRP ARSL ACE
10 chronic thromboembolic pulmonary hypertension 30.6 NPPB EDN1 CRP BMPR2
11 rheumatic fever 30.6 NPPB ALB ACE
12 protein-losing enteropathy 30.5 ZIC3 PTPN11 ALB
13 kawasaki disease 30.5 NPPB CRP ALB
14 pericarditis 30.4 NPPB CRP ALB ACE
15 systolic heart failure 30.4 NPPB EDN1 CRP ACE
16 filariasis 30.4 EDN1 CRP ALB
17 acute myocarditis 30.4 ZIC3 NPPB CRP ACE
18 coronary stenosis 30.3 NPPB CRP ALB ACE
19 hepatopulmonary syndrome 30.3 EDN1 BMPR2 ALB
20 mitral valve disease 30.3 PDZK1IP1 NPPB F2 CRP CPB1 ARSL
21 pulmonary disease, chronic obstructive 30.3 PDE5A NPPB CRP ALB ACE
22 mitral valve insufficiency 30.3 PDZK1IP1 NPPB CRP CPB1 ARSL ALB
23 congestive heart failure 30.2 PDE5A NPPB EDN1 CRP ALB ACE
24 hemopericardium 30.1 F3 F2
25 cerebrovascular disease 30.1 NPPB F2 CRP ACE
26 esophageal varix 30.1 F3 F2 ALB
27 patent ductus arteriosus 1 30.1 ZIC3 PTPN11 PDZK1IP1 NPPB EDN1 CRP
28 sleep apnea 30.1 NPPB EDN1 CRP ALB ACE
29 disseminated intravascular coagulation 30.0 F3 F2 CRP
30 pulmonary valve insufficiency 30.0 WBP2NL PDZK1IP1 NPPB EDN1 CPB1 BMPR2
31 pulmonary edema 30.0 NPPB F2 EDN1 CRP ACE
32 tetralogy of fallot 30.0 ZIC3 PTPN11 NPPB EDN1 CRP ACE
33 lung disease 29.9 NPPB F3 EDN1 CRP ALB ACE
34 liver cirrhosis 29.9 F3 F2 EDN1 ALB
35 eclampsia 29.9 PAPPA F2 EDN1 ALB ACE
36 peripheral artery disease 29.9 NPPB F3 EDN1 CRP ACE
37 bilirubin metabolic disorder 29.9 F3 F2 CRP ALB
38 thrombocytosis 29.9 F3 F2 CRP ALB
39 acute myocardial infarction 29.8 PAPPA NPPB F3 EDN1 CRP ACE
40 arteries, anomalies of 29.7 NPPB F3 EDN1 CRP ALB ACE
41 atrial fibrillation 29.5 NPPB F3 F2 CRP ALB ACE
42 kidney disease 29.5 NPPB F3 EDN1 CRP ALB ACE
43 aortic valve insufficiency 29.5 ZIC3 PDZK1IP1 NPPB CRP CPB1 ARSL
44 cardiac tamponade 29.5 NPPB F3 F2 CRP ALB ACE
45 constrictive pericarditis 29.5 ZIC3 WBP2NL NPPB CRP ARSL ALB
46 dilated cardiomyopathy 29.5 PTPN11 NPPB F2 EDN1 CRP ALB
47 respiratory failure 29.4 NPPB F3 F2 EDN1 CRP ALB
48 pericardial effusion 29.4 PDZK1IP1 NPPB F3 F2 CRP ALB
49 pulmonary embolism 29.3 PDE5A NPPB F3 F2 CRP ALB
50 vascular disease 29.3 NPPB F3 F2 EDN1 CRP BMPR2

Graphical network of the top 20 diseases related to Tricuspid Valve Insufficiency:



Diseases related to Tricuspid Valve Insufficiency

Symptoms & Phenotypes for Tricuspid Valve Insufficiency

MGI Mouse Phenotypes related to Tricuspid Valve Insufficiency:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 ACE ALB BMPR2 CRP EDN1 F2
2 normal MP:0002873 9.32 ALB BMPR2 EDN1 F2 F3 GALNT13

Drugs & Therapeutics for Tricuspid Valve Insufficiency

Drugs for Tricuspid Valve Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tolvaptan Approved Phase 4 150683-30-0 216237
2
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Metolazone Approved Phase 4 17560-51-9 4170
6
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
7
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
8 Arginine Vasopressin Phase 4
9 Torsemide Phase 4
10 Vasopressins Phase 4
11 Sodium Potassium Chloride Symporter Inhibitors Phase 4
12 Hormones Phase 4
13 Anesthetics, Local Phase 4
14 Anesthetics Phase 4
15 Pharmaceutical Solutions Phase 4
16 Central Nervous System Depressants Phase 4
17 Natriuretic Agents Phase 4
18 diuretics Phase 4
19
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
20
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
21
Milrinone Approved Phase 3 78415-72-2 4197
22
Valsartan Approved, Investigational Phase 3 137862-53-4 60846
23
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
25 Kava Approved, Investigational, Nutraceutical Phase 2, Phase 3 9000-38-8
26 Natriuretic Peptide, Brain Phase 3
27 Vasodilator Agents Phase 3
28 Citrate Phase 2, Phase 3
29 Sildenafil Citrate Phase 2, Phase 3 171599-83-0
30 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3
31 Phosphodiesterase Inhibitors Phase 2, Phase 3
32 Protective Agents Phase 3
33 Phosphodiesterase 3 Inhibitors Phase 3
34 Antihypertensive Agents Phase 3
35 Angiotensin Receptor Antagonists Phase 3
36 Angiotensin II Type 1 Receptor Blockers Phase 3
37 Giapreza Phase 3
38 LCZ 696 Phase 3
39 Angiotensinogen Phase 3
40
Nitric Oxide Approved Phase 1 10102-43-9 145068
41
Ambrisentan Approved, Investigational Phase 1 177036-94-1 6918493
42
Glycine Approved, Nutraceutical, Vet_approved Phase 1 56-40-6 750
43 Neurotransmitter Agents Phase 1
44 Anti-Asthmatic Agents Phase 1
45 Autonomic Agents Phase 1
46 Antioxidants Phase 1
47 Free Radical Scavengers Phase 1
48 Respiratory System Agents Phase 1
49 Bronchodilator Agents Phase 1
50
Epinephrine Approved, Vet_approved 51-43-4 5816

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
2 The Effect of Cardiac Pacing Leads on Tricuspid Regurgitation Completed NCT01093001 Phase 4
3 Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation HOVER Trial Recruiting NCT02339974 Phase 4
4 Peripheral Nerve Blocks for Major Lower Extremity Amputations Not yet recruiting NCT03174782 Phase 4 Bupivacaine;Saline Solution
5 Effect of Protocolized Diuretic Strategy on Clinical Outcomes and Health-related Quality of Life in Cardiorenal Failure: A Randomized Trial Terminated NCT01921829 Phase 4 Protocolized Diuretic Strategy
6 Trial of Right Ventricular Versus Modified Blalock-Taussig Shunt in Infants With Single Ventricle Defect Undergoing Staged Reconstruction (A Trial Conducted by the Pediatric Heart Network) Completed NCT00115934 Phase 3
7 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure Completed NCT00270374 Phase 3 nesiritide
8 Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study Completed NCT01156636 Phase 2, Phase 3 Sildenafil;Placebo
9 Comparative Effects of Brief Inhaled Milrinone Versus Intravenous Milrinone on Pulmonary Arterial Pressure in Patients Undergoing Mitral Valve Surgery Completed NCT01621971 Phase 3 inhaled milrinone;intravenous milrinone
10 Postoperative Analgesia After Cardiac Surgery - A Double-Blind, Prospective and Randomized Comparison of Wound Infiltration With Liposomal Bupivacaine and Bupivacaine Hydrochloride Recruiting NCT03270514 Phase 3 Exparel Injectable Product;Bupivacaine Hydrochloride
11 PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction Not yet recruiting NCT04128891 Phase 3 Sacubitril-Valsartan
12 Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve Terminated NCT02387697 Phase 2, Phase 3
13 Catheter Denervation of Pulmonary Arteries in The Treatment of Idiopathic (PAH) & Secondary Pulmonary Hypertension (PH) Unknown status NCT02403908 Phase 1
14 Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™ Completed NCT02098200 Phase 1
15 A Randomized, Placebo-controlled, Study to Evaluate the Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers Completed NCT01673555 Phase 1 GSK1278863;Placebo
16 An Exploratory, 3-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects With WHO Group 3 PH Associated With Idiopathic Pulmonary Fibrosis (IPF) on LTOT (Part 2 and Part 3) Completed NCT02267655 Phase 1 inhaled Nitric Oxide - 30 mcg/kg IBW/hr;inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr;inhaled nitric oxide 75 mcg/kg IBW/hr
17 Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study. Recruiting NCT03406884 Phase 1
18 The Role of Endothelin-1 in Sickle Cell Disease Active, not recruiting NCT02712346 Phase 1 Ambrisentan;Placebo
19 Comparison of Rigid Annuloplasty Ring With a Band in the Correction of Secondary Tricuspid Insufficiency Unknown status NCT03144024
20 The Impact of Right Ventricular Pacing on Tricuspid Regurgitation Unknown status NCT00419354
21 Comparison Between Outcomes Of Ring And Suture Annuloplasty For Functional Tricuspid Regurgitation In Rheumatic Mitral Valve Diseases Unknown status NCT02721524
22 Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) for Symptomatic Chronic Functional Tricuspid Regurgitation Unknown status NCT02574650
23 Prospective, Randomized Evaluation of Prophylactic Tricuspid Valve Annuloplasty in Patients Undergoing Mitral Valve Surgery Unknown status NCT01580436
24 Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart Unknown status NCT01444222
25 Transcatheter Treatment of Severe Tricuspid Regurgitation Using the MitraClip System Unknown status NCT02863549
26 Left Ventricular Pacing to Prevent Iatrogenic Tricuspid Regurgitation Caused by Conventional Right Ventricular Pacing: a Pilot Study Unknown status NCT02314897
27 Long-term Outcome After Isolated Tricuspid Valve Repair Unknown status NCT01537458
28 Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ? Unknown status NCT01947257
29 Evaluation of the Characteristics, Prevalence and Prognosis of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease: Study ETENDARD. Unknown status NCT00434902
30 Non Invasive Detection of Acute Rejection by Circulating microRNAs in Cardiac Transplantation: a Multicenter Prospective Study Unknown status NCT02672683
31 Comparison of Right Ventricular Outflow Tract Gradient Under Anaesthesia With Post-operative Gradient in Patients Undergoing Tetralogy of Fallot Repair Unknown status NCT03234582
32 Cardiac Output and Central Venous Oxygen Saturation Monitoring Using the Vigileo FloTrac Sensor Versus Conventional Thermodilution Method Using the Pulmonary Artery Catheter: A Prospective Study Unknown status NCT00641290
33 Study of the Safety of Flexible Bronchoscopy in Patients With Pulmonary Hypertension Unknown status NCT00986869
34 Quantitative Assessment of Right Ventricular Strain Utilizing Cardiac Magnetic Resonance Imaging: Development of an Optimal Measure of Treatment Response Following Catheter-directed Interventions on Sub-massive Pulmonary Embolism. Unknown status NCT03341208
35 Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis Unknown status NCT01683968
36 Italian Multicenter PROject on Echo Assessment of Left VEntricular (IMPROVE) Dyssynchrony Study Unknown status NCT00646243
37 The Institute of Cardiovascular Surgery Completed NCT01246141
38 A Prospective Randomized Trial of Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Mitral Operation Completed NCT01246947
39 Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial Completed NCT01585779
40 Prognostic Value of Early Postoperative Right Ventricular Systolic Function in Patients With Isolated Severe Tricuspid Regurgitation Completed NCT01203137
41 Prophylactic Tricuspid Annuloplasty During Mitral Valve Surgery Completed NCT03604484
42 EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty Completed NCT01532921
43 Outcome of MC3 Ring Annuloplasty for Moderate and Severe Functional Tricuspid Regurgitation Associated With Rheumatic Mitral Valve Disease Completed NCT04078867
44 Validation Study Comparing the Cardiac Output Pulmonary Arterial Catheter (Swan Ganz) to the FloWave™ 1000 Device Completed NCT00665301
45 Does Acute Normovolemic Hemodilution Affect Intraoperative Value of Serum-creatinine Concentration in Patients Undergoing Cardiac Surgery? Completed NCT02831270 hydroxyethyl starch (HES 130/0.6)
46 Phonokardiographie Bei Erwachsenen Completed NCT03600051
47 Impact of Acute Normovolemic Hemodilution on Whole Blood Coagulation Profile During Post-cardiopulmonary Bypass in Cardiac Surgery: Rotational Thromboelastometry Study Completed NCT02502448 hydroxyethyl starch (HES 130/0.6)
48 Serum Brain Natriuretic Peptide Levels and Its Correlation With Echocardiographic Measurements Suggestive of Pulmonary Hypertension in Pediatric Patients With Sickle Cell Disease Completed NCT01023451
49 Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery Completed NCT00397514
50 MRI Assessment of Two Congenital Heart Disease States: Assessment of Right Ventricular Function: Predictor of Optimal Timing of Pulmonary Valve Replacement in Patients With TOF; Assessment of Flow Dynamics in Patients With Aortic Coarctation Completed NCT00277901

Search NIH Clinical Center for Tricuspid Valve Insufficiency

Cochrane evidence based reviews: tricuspid valve insufficiency

Genetic Tests for Tricuspid Valve Insufficiency

Genetic tests related to Tricuspid Valve Insufficiency:

# Genetic test Affiliating Genes
1 Tricuspid Regurgitation 29

Anatomical Context for Tricuspid Valve Insufficiency

MalaCards organs/tissues related to Tricuspid Valve Insufficiency:

40
Heart, Liver, Lung, Testes, Kidney, Brain, Bone

Publications for Tricuspid Valve Insufficiency

Articles related to Tricuspid Valve Insufficiency:

(show top 50) (show all 5282)
# Title Authors PMID Year
1
Clinical utility of B-type natriuretic peptide for estimating left ventricular filling pressures in unselected elderly patients undergoing diagnostic coronary angiography. 54 61
20197576 2010
2
Prenatal sonographic features of fetuses in trisomy 13 pregnancies. IV. 54 61
20466286 2010
3
Application of classic heart failure definitions of asymptomatic and symptomatic ventricular dysfunction and heart failure symptoms with preserved ejection fraction to patients with systemic right ventricles. 54 61
19616677 2009
4
Elevated serum cobalamin in patients with decompensated biventricular failure. 54 61
19011393 2008
5
Right heart dysfunction assessed with echography, B-type natriuretic peptide and cardiopulmonary test in patients with chronic heart failure. 54 61
18545065 2008
6
B-type natriuretic peptide in patients with systemic right ventricle. 54 61
17934262 2008
7
Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. 54 61
16959341 2007
8
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks. 54 61
16388509 2006
9
[Feasibility of cardiopulmonary rehabilitation in patients with idiopathic pulmonary arterial hypertension treated with intravenous prostacyclin infusion therapy]. 54 61
16320975 2005
10
Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. 54 61
15520111 2004
11
Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. 54 61
12480042 2002
12
Functional Tricuspid Regurgitation or Rare Congenital Condition? 61
31761654 2020
13
Ventricular Pacing-Induced Tricuspid Regurgitation After Cardiopulmonary Bypass. 61
31500978 2020
14
Tricuspid regurgitation and long-term clinical outcomes. 61
31544933 2020
15
Tricuspid regurgitation: finally unforgettable! 61
31625575 2020
16
TriClip system reduces tricuspid regurgitation. 61
31784710 2020
17
Clinical Impact of Size, Shape, and Orientation of the Tricuspid Annulus in Tricuspid Regurgitation as Assessed by Three-Dimensional Echocardiography. 61
31837928 2020
18
Computed tomography for transcatheter tricuspid valve development. 61
31451974 2020
19
Durability and Efficacy of Tricuspid Valve Repair in Patients Undergoing Left Ventricular Assist Device Implantation. 61
31838034 2020
20
Identifying patients likely to be readmitted after transcatheter aortic valve replacement. 61
31649048 2020
21
Effect of Concomitant Tricuspid Valve Surgery with Left Ventricular Assist Device Implantation. 61
32035052 2020
22
Prediction of Perinatal Mortality in Ebstein's Anomaly Diagnosed in the Second Trimester of Pregnancy. 61
32018269 2020
23
Right ventricular-pulmonary arterial uncoupling in mild-to-moderate systemic hypertension. 61
31568058 2020
24
Tricuspid valve repair in children with hypoplastic left heart syndrome: impact of timing and mechanism on outcome. 61
32031596 2020
25
Fetal echocardiographic prediction score for perinatal mortality in tricuspid valve dysplasia and Ebstein's anomaly. 61
31008542 2020
26
Effect of Pulmonary Hypertension on Clinical Outcomes in Patients With Rheumatic Mitral Stenosis. 61
31336071 2020
27
Reply to: "Appraisal of cardiac ejection fraction with liver disease severity". 61
32020634 2020
28
Familial Mitral Arcade, Tricuspid Dysplasia, Left Ventricular Noncompaction and Short-Chain Acyl-CoA Reductase Deficiency. 61
31870493 2020
29
Continuous-Flow Left Ventricular Assist Devices and Valvular Heart Disease: A Comprehensive Review. 61
32036866 2020
30
Aortic Stenosis with Other Concomitant Valvular Disease: Aortic Regurgitation, Mitral Regurgitation, Mitral Stenosis, or Tricuspid Regurgitation. 61
31753175 2020
31
Biatrial vs. bicaval orthotopic heart transplantation: a systematic review and meta-analysis. 61
32035050 2020
32
Fetal tricuspid regurgitation in second trimester of pregnancies at risk for fetal chromosomal defects. 61
31282053 2020
33
Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease. 61
31848778 2020
34
Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity. 61
32019991 2020
35
Is the diameter of tricuspid annulus or functional tricuspid regurgitation the key parameter for performing 'prophylactic annuloplasty'? 61
30863866 2020
36
Ventriculoatrial Shunt Catheter Tip Migration Causing Tricuspid Regurgitation: Case Report and Review of the Literature. 61
31931241 2020
37
The economic impact of clinically significant tricuspid regurgitation in a large, administrative claims database. 61
31952454 2020
38
Transcatheter tricuspid annuloplasty with the Cardioband device to treat severe functional tricuspid regurgitation. 61
31974069 2020
39
Managing Combined Mitral and Tricuspid Regurgitation: Should We Clip the Percutaneous Clip Procedures? 61
31954668 2020
40
Impact of Tricuspid Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement. 61
31954675 2020
41
Outcomes after surgery for functional tricuspid regurgitation: a systematic review and meta-analysis. 61
31287501 2020
42
Isolated reoperation for tricuspid regurgitation after left-sided valve surgery: technique evolution. 61
31157373 2020
43
Commentary: Late tricuspid valve insufficiency following mitral valve repair: A marker or a cause for inferior outcome? 61
32008761 2020
44
Outcomes Following Tricuspid Valve Repair with Ring Versus Suture Bicuspidization Annuloplasty. 61
32001230 2020
45
Prevalence of right ventricular outflow tract abnormalities among recipients in twin-twin transfusion syndrome after fetoscopic laser surgery in 90 consecutive cases. 61
31641903 2020
46
Giant right coronary artery aneurysm mimicking a right intra-ventricular mass: a case report. 61
31931838 2020
47
Algorithm for the analysis of pre-extraction computed tomographic images to evaluate implanted lead-lead interactions and lead-vascular attachments. 61
31931170 2020
48
Determinants of changes in pulmonary artery pressure in patients with severe aortic stenosis treated by transcatheter aortic valve implantation. 61
31920151 2020
49
Compressed sensing real-time cine imaging for assessment of ventricular function, volumes and mass in clinical practice. 61
31372784 2020
50
Letter by Fayssoil Regarding Article, "Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction". 61
31887075 2020

Variations for Tricuspid Valve Insufficiency

ClinVar genetic disease variations for Tricuspid Valve Insufficiency:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PTPN11 NM_002834.4(PTPN11):c.184T>G (p.Tyr62Asp)SNV Pathogenic 13329 rs121918460 12:112888168-112888168 12:112450364-112450364
2 46;XX;ins(5;6)(p13;p24p25)dnTranslocation Pathogenic 267851
3 MYH11 NM_002474.3(MYH11):c.4360G>C (p.Asp1454His)SNV Likely pathogenic 374162 rs1057518938 16:15818023-15818023 16:15724166-15724166
4 GATA4 NM_002052.5(GATA4):c.1273G>A (p.Asp425Asn)SNV Conflicting interpretations of pathogenicity 9034 rs56208331 8:11615928-11615928 8:11758419-11758419
5 46;XX;inv(14)(q24.1q32.1)dninversion Uncertain significance 267889

Expression for Tricuspid Valve Insufficiency

Search GEO for disease gene expression data for Tricuspid Valve Insufficiency.

Pathways for Tricuspid Valve Insufficiency

Pathways related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.28 PTPN11 EDN1 CRP

GO Terms for Tricuspid Valve Insufficiency

Cellular components related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 PAPPA NPPB F3 F2 EDN1 CRP
2 extracellular space GO:0005615 9.32 PAPPA NPPB F3 F2 EDN1 CRP

Biological processes related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of renal sodium excretion GO:0035815 9.4 NPPB EDN1
2 positive regulation of urine volume GO:0035810 9.37 NPPB EDN1
3 negative regulation of systemic arterial blood pressure GO:0003085 9.32 NPPB BMPR2
4 negative regulation of hormone secretion GO:0046888 9.26 PTPN11 EDN1
5 positive regulation of hormone secretion GO:0046887 9.16 PTPN11 EDN1
6 body fluid secretion GO:0007589 8.96 NPPB EDN1
7 regulation of blood pressure GO:0008217 8.92 NPPB MC3R EDN1 ACE

Sources for Tricuspid Valve Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....